Arbutus Biopharma
ABUS
114 hedge funds and large institutions have $126M invested in Arbutus Biopharma in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 48 increasing their positions, 30 reducing their positions, and 24 closing their positions.
112% more call options, than puts
Call options by funds: $3.74M | Put options by funds: $1.77M
60% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 30
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
43% more capital invested
Capital invested by funds: $88.4M → $126M (+$37.9M)
3.56% more ownership
Funds ownership: 31.09% → 34.65% (+3.6%)
10% less funds holding
Funds holding: 127 → 114 (-13)
54% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 24
Top Buyers
| 1 |
WCM
Whitefort Capital Management
New York
|
+$9.21M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$8.29M |
| 3 |
TSC
Two Seas Capital
Rye,
New York
|
+$4.43M |
| 4 |
BlackRock
New York
|
+$2.95M |
| 5 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$1.43M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$3.97M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.58M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$751K |
| 4 |
Goldman Sachs
New York
|
-$639K |
| 5 |
Parallax Volatility Advisers
San Francisco,
California
|
-$383K |
ABUS Hedge Fund Activity: Q4 2022 in Review
114 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2022, worth a combined $126M — up 43% from $88.4M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ABUS and 11 opened new positions — a net loss of 13 holders — while 30 trimmed existing stakes and 48 added.
The largest buyer was Whitefort Capital Management, opening a new position worth an estimated $9.21M. The largest seller was Millennium Management, cutting an estimated $3.97M.
- 114 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2022, down from 127 in Q3 2022.
- Funds reported $126M of Arbutus Biopharma stock for Q4 2022, up 43% quarter-over-quarter.
- 11 funds opened new Arbutus Biopharma positions in Q4 2022 and 24 closed out, a net change of -13 holders.
- The largest Arbutus Biopharma buyer in Q4 2022 was Whitefort Capital Management, an estimated $9.21M added.
- The largest Arbutus Biopharma seller in Q4 2022 was Millennium Management, an estimated $3.97M sold.
Based on aggregated 13F filings for Q4 2022.